06:04 , Jun 10, 2019 |  BC Extra  |  Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
21:29 , May 10, 2019 |  BC Extra  |  Company News

Management tracks: Roche veteran Chen joins Everest, CBC Group; plus G1, Rani

Everest Medicines Ltd. (New York, N.Y.) hired Wende Chen as chief commercial officer. He will also serve as an operating partner at CBC Group (formerly C-Bridge Capital), the company's founding investor. Chen was VP of...